Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 6/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.81 |
| ▸ | PGR | P06401 | 5/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.81 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.81 |
| ▸ | HPGD | P15428 | 1/20 | 0.81 |
| ▸ | MLNR | O43193 | 1/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.81 |
| ▸ | SHBG | P04278 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20101055 | 0.92 | NR3C1 (0.88) | ARLMNACYP3A4NR3C1PGR | |
| SCHEMBL11511136 | 0.92 | LMNA (0.78) | ARLMNACYP3A4NR3C1PGR | |
| SCHEMBL11229308 | 0.92 | AR (0.89) | ARLMNACYP3A4NR3C1PGR | |
| SCHEMBL11020429 | 0.92 | AR (0.89) | ARLMNACYP3A4NR3C1PGR | |
| SCHEMBL17519899 | 0.91 | LMNA (0.96) | ARLMNACYP3A4NR3C1PGR | |
| SCHEMBL11510015 | 0.91 | LMNA (0.77) | ARLMNACYP3A4NR3C1PGR | |
| SCHEMBL571389 | 0.91 | LMNA (0.77) | ARLMNACYP3A4NR3C1PGR | |
| SCHEMBL11510625 | 0.91 | LMNA (0.77) | ARLMNACYP3A4NR3C1PGR | |
| Clascoterone SCHEMBL25297448 | 0.90 | AR (1.00) | ARLMNACYP3A4NR3C1PGR | |
| Clascoterone SCHEMBL24688164 | 0.90 | AR (1.00) | ARLMNACYP3A4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114126710-A | Segmented intravaginal EVA ring containing progesterone | B·马特尔 | 2022-03-01 | — | — | CN | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| US-20040250300-A1 | Expression of proteins in milk | PHARMING B.V. (NL) | 2004-12-09 | — | — | US | disclosed |
| US-20020129387-A1 | EXPRESSION OF PROTEINS IN MILK | PHARMING INTELLECTUAL PROPERTY B.V. (NL) | 2002-09-12 | — | — | US | disclosed |
| US-5750172-A | Transgenic non human mammal milk | PHARMING B.V. (NL) | 1998-05-12 | — | — | US | disclosed |
| EP-0347431-B1 | EXPRESSION OF PROTEINS IN MILK | GENE PHARMING EUROP BV (NL) | 1995-10-04 | — | — | EP | disclosed |
| US-4873316-A | Isolation of exogenous recombinant proteins from the milk of transgenic mammals | BIOGEN, INC. (US) | 1989-10-10 | — | — | US | disclosed |
| WO-1988010118-A1 | EXPRESSION OF PROTEINS IN MILK | BIOGEN N.V. (AN) | 1988-12-29 | — | — | WO | disclosed |
| EP-0036145-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1985-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | AR 3036/4885LMNA 3003/4885CYP3A4 2764/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | AR 3036/4885LMNA 3003/4885CYP3A4 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.